There is a major, unmet need for the treatment of cancer pain, and new targets and
medicines are required. The transient receptor potential ankyrin 1 (TRPA1), a cation channel …

Breast carcinoma causes severe pain, which decreases the quality of life of patients. Current
treatments produce adverse effects and have limited efficacy. Transient potential receptor …

Background: Bone cancer pain (BCP) significantly affects patient quality of life, results in
great bodily and emotional pain, and creates difficulties in follow-up treatment and normal …

Antineoplastic therapy has been associated with pain syndrome development characterized
by acute and chronic pain. The chemotherapeutic agent dacarbazine, used mainly to treat …

Aims Breast cancer-induced chronic pain is usually treated with opioids, but these
compounds cause various adverse effects. Transient receptor potential ankyrin 1 (TRPA1) is …

Transient receptor potential (TRP) channels are critical receptors in the transduction of
nociceptive stimuli. The microenvironment of diverse types of cancer releases substances …

To investigate the mechanisms underlying cancer pain, we developed a rat model of cancer
pain by inoculating SCC-158 into the rat hind paw, resulting in squamous cell carcinoma …

Transient receptor potential ankyrin 1 (TRPA1) is a polymodal cation channel that is
activated by electrophilic irritants, oxidative stress, cold temperature, and GPCR signaling …

Background: Cisplatin is primarily used for treatment of ovarian and testicular cancer.
Oxaliplatin is the only effective treatment for metastatic colorectal cancer. Both are known to …

The transient receptor potential ankyrin 1 (TRPA1) channel has been implicated in
pathophysiological processes that include asthma, cough, and inflammatory pain. Agonists …